# Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

> **NCT06929507** · NA · RECRUITING · sponsor: **University Hospital, Alexandroupolis** · enrollment: 60 (estimated)

## Conditions studied

- Renal Function Disorder
- Diabetic Macular Edema (DME)
- Neovascular Age Related Macular Degeneration

## Interventions

- **DRUG:** Intravitreal injection of Faricimab or Aflibercept 2 mg

## Key facts

- **NCT ID:** NCT06929507
- **Lead sponsor:** University Hospital, Alexandroupolis
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-03-10
- **Final completion:** 2027-03-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06929507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06929507, "Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06929507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*